Chemical restraint

What is chemical restraint?

Chemical restraint is the use of medication or a chemical substance for the primary purpose of influencing a person's behaviour. It is one of the five regulated restrictive practices in the NDIS. Medication prescribed by a medical practitioner to treat, or to enable treatment of, a diagnosed mental disorder, a physical illness or a physical condition is not chemical restraint.

That definition comes from section 6(b) of the NDIS (Restrictive Practices and Behaviour Support) Rules 2018. It sits alongside seclusion and mechanical, physical and environmental restraint as a regulated restrictive practice. When a medication meets the definition, a registered provider can only give it under a behaviour support plan, with state or territory authorisation, and it must record and report each use.

The term matters to three groups:

• Participants and families, who have a right to know why a medication is given and whether it is being used to change behaviour rather than treat a condition.
• Support workers, who give the medication and must follow the plan's protocol exactly.
• Providers, who carry the registration conditions: authorisation, records, monthly reporting and incident notification.

How the chemical restraint test works

The test is about purpose, not the drug. The same medicine can be chemical restraint for one person and treatment for another. The Rules ask one question: is the primary purpose to influence behaviour? If yes, and no treatment exclusion applies, it is regulated.

The prescriber decides the clinical purpose. The NDIS Commission's Regulated Restrictive Practices Guide tells providers to ask the prescriber directly why a medication was prescribed, and when and how it should be given, if that is unclear. Keep the answer on file. Examples drawn from the Commission's guide:

Watch for orders whose wording drifts from treatment to behaviour, such as "PRN for settling" or "when unsettled at night". They often signal a behavioural purpose that has never been through a plan or authorisation.

Routine and PRN chemical restraint

Chemical restraint can be routine (a regular, scheduled dose) or PRN (given only when certain behaviours occur). Both are regulated. A PRN chemical restraint needs a written protocol in the plan that sets out the less restrictive strategies to try first, the observable behaviours that justify a dose, the dose limits from the medication chart, monitoring for side effects, and a plan to fade the medication out over time.

What providers must do when medication is chemical restraint

Chemical restraint carries the same conditions as every other regulated practice. They are conditions of registration under Part 2 of the Rules, and only registered providers audited against Module 2A of the NDIS Practice Standards may implement them.

1. A behaviour support plan. The practice must be in an interim or comprehensive plan written by a behaviour support practitioner and lodged with the NDIS Commission. If it has been used and will continue, the provider must take all reasonable steps to have an interim plan within 1 month and a comprehensive plan within 6 months of first use.
2. State or territory authorisation. The implementing provider obtains it and lodges evidence with the Commission. A single emergency use is exempt from the authorisation condition, but is still reportable.
3. A record of every use. Section 15 requires the behaviour, the reason, less restrictive options tried, times, place, people involved, witnesses, impact, injury and actions before and after. Records are kept for 7 years.
4. Monthly reporting. Use is reported to the Commission each month. Its portal guidance asks for each PRN administration to be reported separately, within 5 business days of month end, including "not used" months.

The medication administration record does not replace the restrictive practice record. One shows the dose; the other shows why it was given. Link them so an auditor can move from one to the other. Good medication management systems make this link routine.

Chemical restraint vs other restrictive practices

The key difference from physical or mechanical restraint is that the restriction is invisible. Nobody holds the person and no device is fitted, so chemical restraint is the easiest regulated practice to miss. It also has effects that last well beyond the moment of use, such as sedation, falls risk and weight gain, which is why the plan must include monitoring and a review with the prescriber.

Authorisation differs by state and territory

The NDIS Commission does not authorise chemical restraint. Each state and territory does, under its own law or policy, and some have their own prohibited practices. The pattern, based on the 2025 national summary of authorisation frameworks:

• Provider-convened panels with an independent member authorise in NSW and WA.
• A provider's Authorised Program Officer can authorise chemical restraint in Victoria; in South Australia APOs authorise lower-level practices and a Senior Authorising Officer the rest.
• Guardianship-based consent applies in Queensland, where longer-term chemical restraint needs consent from a guardian for a restrictive practice, and the department can give short-term approvals.
• A Senior Practitioner authorises in Tasmania and the NT; in the ACT a registered panel approves and the Senior Practitioner registers the plan.

NSW, for example, lists "misuse of medication" — giving medication prescribed to influence behaviour contrary to the prescriber's instructions — as prohibited. Frameworks change, so confirm the current process with your state before relying on any summary.

When chemical restraint becomes a reportable incident

Giving a chemical restraint outside the plan or without authorisation is a reportable incident under section 16 of the Incident Management and Reportable Incidents Rules. Examples: a PRN given before the less restrictive steps were tried, a dose above the stated maximum, a dose for a behaviour not listed in the indicators, or use under an expired authorisation. Notify the Commission within 5 business days of becoming aware. If the person was seriously injured, for example by over-sedation leading to a fall, that part must be notified within 24 hours. The free reportable incident checker confirms the category and the deadline.

A change to dose or frequency also needs care. The Commission's monthly reporting guide says a change that does not need re-authorisation in your state can be reported as a variation, but a change that does, or any use not in accordance with the plan, is a reportable incident. When a prescriber changes a medication, check both the plan and the authorisation before the next dose.

Common mistakes

• Assuming a prescription settles it. A doctor's order shows the medication is lawful to give, not that it is outside the Rules. Purpose decides.
• Missing routine doses. Providers often track PRN well but forget a daily medication given for behaviour.
• Vague PRN indicators such as "if agitated", which make it impossible to show use was in line with the plan.
• Not involving the prescriber in reduction. The plan must aim to reduce and eliminate the practice, and only the prescriber can change the medication.
• Mistaking side effects for behaviours of concern, which can lead to more medication rather than less.

For a first pass on a real situation, the free restrictive practice checker walks through the questions and dates.